Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM7GCVW)

Drug Name
Acalabrutinib Drug Info
Synonyms
Calquence; UNII-I42748ELQW; I42748ELQW; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Calquence (TN); Acalabrutinib(ACP196); Acalabrutinib (ACP-196); GTPL8912; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; WDENQIQQYWYTPO-IBGZPJMESA-N; KS-000006AT; KS-000006AD; s8116; BDBM50175583; AKOS030526094; ZINC208774715; DB11703; CS-5356; DS-3326
Cross-matching ID
PubChem CID
71226662
ChEBI ID
CHEMBL3707348
CAS Number
CAS 1420477-60-6
TTD Drug ID
D09PQZ
INTEDE Drug ID
DR0031
ACDINA Drug ID
D00005

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
PPAR signaling pathway 2.10 8.36e-3 66/74 (89.19%) FABP4;PPARG;CD36;...
Mismatch repair 2.07 4.18e-3 22/23 (95.65%) PCNA;RFC3;LIG1;...
DNA replication 2.04 5.57e-3 34/36 (94.44%) PCNA;RFC3;LIG1;...
Tryptophan metabolism -1.61 4.49e-2 35/42 (83.33%) AOX1;CYP1A1;KMO;...
Shigellosis -1.61 4.53e-2 180/246 (73.17%) HCLS1;RELA;PIK3R2;...
T cell receptor signaling pathway -1.62 4.65e-2 93/104 (89.42%) NFATC1;GRB2;NFKBIB;...
VEGF signaling pathway -1.65 3.54e-2 50/59 (84.75%) MAPK3;MAPK1;KDR;...
Apoptosis -1.67 3.11e-2 126/168 (75%) BIRC7;NGFR;ITPR3;...
C-type lectin receptor signaling pathway -1.67 3.10e-2 93/104 (89.42%) PTPN11;CASP1;NFATC1;...
TGF-beta signaling pathway -1.68 3.09e-2 81/94 (86.17%) PITX2;MAPK3;MAPK1;...
Sphingolipid signaling pathway -1.72 1.95e-2 106/119 (89.08%) SMPD2;GNAI3;MAPK3;...
Lysosome -1.74 1.58e-2 115/128 (89.84%) DNASE2B;CTSH;LAPTM4A;...
Necroptosis -1.76 1.34e-2 113/159 (71.07%) TYK2;CASP1;SLC25A6;...
Toxoplasmosis -1.79 1.07e-2 103/112 (91.96%) BIRC7;NFKBIB;GNAI3;...
Sphingolipid metabolism -1.80 8.87e-3 32/49 (65.31%) SGPL1;ASAH1;GAL3ST1;...
Chagas disease -1.85 5.61e-3 93/102 (91.18%) GNA14;GNAI3;MAPK3;...
Tuberculosis -1.86 5.28e-3 159/180 (88.33%) TCIRG1;NFYB;ITGAM;...
TNF signaling pathway -1.87 4.91e-3 103/112 (91.96%) MAPK3;CSF1;MAPK1;...
Leishmaniasis -1.92 2.99e-3 67/77 (87.01%) ITGAM;NFKBIB;HLA-DOB;...
Antigen processing and presentation -1.92 3.21e-3 60/78 (76.92%) CTSS;KLRC3;HSPA1L;...
Osteoclast differentiation -1.93 3.46e-3 117/127 (92.13%) RELA;IFNGR1;PIK3R2;...
Allograft rejection -1.93 3.74e-3 32/38 (84.21%) HLA-DOB;HLA-B;PRF1;...
Intestinal immune network for IgA production -1.93 3.06e-3 38/48 (79.17%) TNFSF13;HLA-DMB;IL6;...
IL-17 signaling pathway -1.94 3.37e-3 84/94 (89.36%) MAPK3;MAPK1;TAB2;...
Type I diabetes mellitus -1.99 1.25e-3 38/43 (88.37%) HLA-DOB;HLA-B;PRF1;...
Cocaine addiction -2.00 1.40e-3 42/49 (85.71%) ATF2;MAOA;CDK5;...
Th1 and Th2 cell differentiation -2.03 0.00e+0 80/92 (86.96%) TYK2;NFATC1;NFKBIB;...
Inflammatory bowel disease -2.07 0.00e+0 58/65 (89.23%) NFATC1;HLA-DOB;IL4R;...
Asthma -2.08 0.00e+0 25/31 (80.65%) RNASE3;TNF;EPX;...
NF-kappa B signaling pathway -2.11 0.00e+0 90/104 (86.54%) CCL19;GADD45B;TLR4;...
Th17 cell differentiation -2.12 0.00e+0 95/107 (88.79%) TYK2;NFATC1;NFKBIB;...
Graft-versus-host disease -2.13 0.00e+0 32/42 (76.19%) HLA-A;KLRD1;HLA-DOB;...
Rheumatoid arthritis -2.21 0.00e+0 78/93 (83.87%) TCIRG1;ATP6V1E1;HLA-DOB;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.08uM - 10uM 6H, 24H, 48H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
K-562 CVCL_0004 Homo sapiens 0.01uM - 10uM 24H
Multiple myeloma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
KMS-34 CVCL_1333 Homo sapiens 0.01uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.08uM - 10uM 6H, 24H, 48H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.08uM - 10uM 6H, 24H, 48H
Lymph node
Burkitt lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BJAB CVCL_5711 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HBL-1 CVCL_4213 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly10 CVCL_8795 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly19 CVCL_8797 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly3 CVCL_8796 Homo sapiens 0.01uM - 10uM 24H
TMD8 CVCL_A440 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Mantle cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MINO CVCL_4965 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Peripheral blood
Acute B-lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NALM-6 CVCL_0092 Homo sapiens 0.01uM - 10uM 24H
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-MEL-5 CVCL_0527 Homo sapiens 0.01uM - 10uM 24H